The BANK of Greenland’s report for the first half of 2026
Result for the first half of 2026 The BANK of Greenland’s profit before tax amounts to DKK 97.4…
Greenland Technologies Reports Strong Second Quarter and First Half 2026 Financial Results
Q2 Revenue Increased 37.6% Year Over Year to $29.9 Million Q2 Gross Profit Increased 65.9% to $9.5 Million;…
Maersk Tankers and HD Hyundai Samho Celebrate First Large Ammonia Carrier
Maersk Tankers and shipbuilder HD Hyundai Samho each celebrated milestones with the delivery of the first large ammonia…
“Love has no borders”: Maximá of the Netherlands, first queen to participate in Pride Day
You might be interested in Holaluz: what happened to the ‘rooftop revolution’? Barcelona”Love knows no borders”: this was…
Greenland Mines Reports 36-44% PdEq Grade Uplift and +31% Increase in Indicated PdEq Ounces at its Skaergaard Gold, Palladium, Platinum Project in First S-K 1300 Technical Report Summary
Updated 2026 MRE reflects strong grade and contained-metal increases versus 2022 baseline; S-K 1300 conversion establishes U.S. regulatory…
Novo Nordisk Scores UK First for Oral Wegovy, but Pipeline and Price Pressures Cap the Rally
Novo Nordisk has secured a landmark regulatory nod for its oral version of Wegovy in Britain, yet the…
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults…
TGS Begins First Phase of Major Offshore Seismic Dataset in Equatorial Guinea
Oslo, Norway (10 June, 2026) TGS, a leading provider of energy data and intelligence, today announced the signing of an…
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral…
Novo Nordisk Faces First Generic Challenge in Canada as Wegovy Oral Pill Dominates US Market
Novo Nordisk’s US Wegovy surges with 65% of new scripts, raising guidance, but Canadian Ozempic generic approval threatens…
AS Tallinna Vesi held an investor conference webinar to introduce the results of the first quarter of 2026
Today, on 8 May 2026, AS Tallinna Vesi held an investor conference webinar where Chairman of the Management…
Novo Nordisk’s Pill Pivot Faces Its First Big Test on Wednesday
Novo Nordisk’s shift to oral GLP-1 drugs faces pricing pressure and Eli Lilly competition as Q1 earnings loom,…